GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells

GZ17-6.02 is presently undergoing clinical evaluation in solid tumors and lymphoma. The present studies were performed to define its biology in estrogen receptor positive breast cancer cells and to determine whether it interacted with palbociclib to enhance tumor cell killing. GZ17-6.02 interacted i...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, West, Cameron, Moore, Robert P., Von Hoff, Daniel, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754587/
https://www.ncbi.nlm.nih.gov/pubmed/35035775
http://dx.doi.org/10.18632/oncotarget.28177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754587/
https://www.ncbi.nlm.nih.gov/pubmed/35035775
http://dx.doi.org/10.18632/oncotarget.28177

Ejemplares similares